Elutia Inc. (ELUT) - Form 10-Q Summary
Business Context and Reporting Period
This Quarterly Report covers the period ended June 30, 2026. Elutia Inc. is a commercial-stage company developing drug-eluting biomatrix products for surgical reconstruction. The company operates in two segments: Women's Health (SimpliDerm) and Cardiovascular (ProxiCor, VasCure, Tyke). The company recently divested its Cardiac Implantable Electronic Device (CIED) business in October 2025 and is currently negotiating the sale of its SimpliDerm business.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (in thousands) |
|---|---|
| Net Sales | $5,541 |
| Gross Profit | $3,249 |
| Gross Margin | 58.6% |
| Net Loss | $(15,115) |
| Operating Cash Flow | $(16,292) |
| Cash and Cash Equivalents | $19,896 |
| Total Liabilities | $27,903 |
| Stockholders' Equity | $15,746 |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 2.8% to $5.5 million compared to $5.7 million in the prior year. This was driven by a 27.3% decline in Women's Health sales (due to supply disruptions and termination of a distribution agreement) partially offset by a 104.2% increase in Cardiovascular sales (due to a shift to direct sales at higher end-user pricing).
- Profitability: Gross margin improved to 58.6% from 49.8% year-over-year, primarily due to the shift to direct sales models. However, the Net Loss increased to $15.1 million from $13.5 million, driven by higher R&D expenses and warrant liability revaluations.
- Expenses: Research and Development (R&D) expenses surged 141.9% to $4.5 million due to accelerated development of NXT-41 and NXT-41x. Litigation costs decreased 59.5% to $2.7 million as FiberCel cases were largely settled.
- Balance Sheet: Cash decreased by $16.5 million due to operating losses. The company fully repaid its SWK Loan Facility in October 2025 using proceeds from the CIED divestiture.
Guidance, Outlook, and Risks
- Strategic Divestitures: On July 16, 2026, Elutia entered an agreement to sell its SimpliDerm business for up to $11 million (base $8M + milestones/earn-outs). Closing is expected in Q3 2026. The company is also exploring the divestiture of its Cardiovascular product line.
- Product Development: Focus has shifted to the Drug-Eluting Biomatrix (DEB) platform, specifically NXT-41 and NXT-41x (antibiotic-eluting). No FDA clearance has been received yet.
- Liquidity and Financing: On August 11, 2026, the company secured a new senior secured term loan facility of up to $15 million ($10M initial tranche funded). Management believes current cash plus new loan proceeds will fund operations for at least one year.
- Listing Status: The company received a Nasdaq notice on August 6, 2026, regarding failure to meet the $1.00 minimum bid price requirement. It has 180 days (until Feb 2, 2027) to regain compliance.
- Litigation: Significant contingent liabilities remain related to FiberCel and VBM product recalls. While insurance covers VBM costs, FiberCel insurance is exhausted. A settlement with Medtronic was reached in July 2026 for $1.78 million.
Investor Verification Checklist
- SimpliDerm Sale Closing: Verify the consummation of the SimpliDerm asset sale and the receipt of the $8 million base purchase price.
- Nasdaq Compliance: Monitor stock price to ensure it meets the $1.00 minimum bid requirement or confirm a reverse stock split plan before the February 2027 deadline.
- Debt Covenants: Review the terms of the new $15 million Avenue loan, specifically the interest rate (12.25% + Prime) and prepayment penalties.
- Litigation Exposure: Assess the potential for additional FiberCel liabilities beyond the accrued $1.1 million, given the lack of remaining insurance coverage.
- R&D Milestones: Track progress on FDA clearance for NXT-41 and NXT-41x, which are critical for future revenue growth post-divestiture.